Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients.
Randomized clinical trials evaluated the role of anticoagulants in the prevention of venous thromboembolism in ambulatory cancer patients treated with chemotherapy. This meta-analysis is aimed at providing an updated evaluation of the efficacy and safety of anticoagulant prophylaxis in this clinical setting. Medline and Scopus were searched to retrieve randomized controlled trials on the prevention of venous thromboembolism in ambulatory cancer patients. Two groups of trials were identified with venous thromboembolism or death as primary outcome, respectively. Venous thromboembolism was the primary outcome of this analysis. Anticoagulant prophylaxis reduced the incidence of venous thromboembolism in studies with venous thromboembolism (14 studies, 8226 patients, OR 0.45; 95% CI 0.36-0.56) or death as primary outcome (8 studies, 3727 patients, OR 0.61; 95% CI 0.47-0.81). When these studies were pooled together, venous thromboembolism was reduced by 49% (95% CI 0.43-0.61) with no significant increase in major bleeding (OR 1.30, 95% CI 0.98-1.73). The risk of major bleeding was increased in studies with venous thromboembolism as primary outcome (OR 1.43, 95% CI 1.01-2.04). Similar reductions of venous thromboembolism were observed in studies with parenteral (OR 0.43; 95% CI 0.33-0.56) or oral anticoagulants (OR 0.49; 95% CI 0.33-0.74). Venous thromboembolism reduction was confirmed in patients with lung (OR 0.42, 95% CI 0.26-0.67) or pancreatic cancer (OR 0.26; 95% CI 0.14-0.48), in estimated high-risk patients, in high-quality studies and with respect to symptomatic venous thromboembolism. Prophylaxis with oral or parenteral anticoagulants reduces the risk of venous thromboembolism in ambulatory cancer patients with acceptable increase in major bleeding.